May 24, 2020
HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China
Mar 03, 2020
MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a Humanized Mouse Model
Feb 25, 2020
Clinical Study Supports Bergacyn® for Liver and Vascular Health
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Oct 21, 2019
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019
Oct 03, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight(TM) Human Liver Disease platform
Sep 24, 2019
PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH
May 22, 2019
Scientists Identify New Therapeutic Target for Fatty Liver Disease
Feb 20, 2019
Amsety and Fatty Liver Foundation are Partnering to Raise Funds for Liver Health Awareness Through the KISS AND CLICK Challenge
Nov 19, 2018
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
Oct 24, 2018
TaiwanJ Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Study of JKB-122 on Non-Alcoholic Fatty Liver Disease (NAFLD)
May 18, 2018
HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development
Apr 25, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
Apr 14, 2018
NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
Apr 13, 2018
GNS Healthcare to Present Results on Prediction of Disease Progression Using AI in NASH Patients at The International Liver Congress(TM)
Mar 12, 2018
NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Oct 19, 2017
NGM Bio Provides Update On NGM282 In NASH
Sep 22, 2017
New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial